

Takeda Hellas S.A.

Disclosure Year: 2023

Date of Publication: 30-Jun-2024

	Full Name <i>(Art.1.01)</i>	HCPs: City of Principal Practice HCOs: City where registered <i>(Art.3)</i>	Country of Principal Practice <i>(Schedule1)</i>	Principal Practice Address <i>(Art.3)</i>	Unique country identifier OPTIONAL <i>(Art.3)</i>	Donations and Grants to HCOs <i>(Art. 3.01.1.a)</i>	Contribution to costs of Events <i>(Art. 3.01.1.b & 3.01.2.a)</i>			Fee for service and consultancy <i>(Art. 3.01.1.c & 3.01.2.c)</i>		TOTAL OPTIONAL	
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract		
HCPs	<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up. Itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>												
	<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>												
	Aggregate amount attributable to transfers of value to such Recipients - <i>Art. 3.02</i>						N/A	N/A					
	Number of Recipients in aggregate disclosure - <i>Art. 3.02</i>						N/A	N/A					
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - <i>Art. 3.02</i>						N/A	N/A					N/A	
HCOs	<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up. Itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>												
	KΥΤΡΙΑΚΗ ΑΙΜΑΤΟΛΟΓΙΚΗ ΕΤΑΙΡΕΙΑ	CYPRUS	Cyprus	CYPRUS			2,000.00					2,000.00	
	<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>												
	Aggregate amount attributable to transfers of value to such Recipients - <i>Art. 3.02</i>												
Number of Recipients in aggregate disclosure - <i>Art. 3.02</i>													
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - <i>Art. 3.02</i>												N/A	
R&D	AGGREGATE DISCLOSURE												
	Transfers of Value re Research & Development as defined - Article 3.04 and Schedule 1											0.00	2,000.00